2,804 Shares in Bruker Co. (NASDAQ:BRKR) Bought by Covenant Partners LLC

Covenant Partners LLC purchased a new stake in Bruker Co. (NASDAQ:BRKRFree Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,804 shares of the medical research company’s stock, valued at approximately $206,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Iron Triangle Partners LP lifted its position in shares of Bruker by 4.4% during the 4th quarter. Iron Triangle Partners LP now owns 450,000 shares of the medical research company’s stock worth $33,066,000 after purchasing an additional 19,157 shares during the last quarter. Point72 Europe London LLP acquired a new position in shares of Bruker during the 4th quarter worth about $9,846,000. Neuberger Berman Group LLC increased its holdings in shares of Bruker by 0.9% in the 4th quarter. Neuberger Berman Group LLC now owns 24,438 shares of the medical research company’s stock valued at $1,796,000 after acquiring an additional 219 shares during the last quarter. Nomura Holdings Inc. acquired a new stake in shares of Bruker during the 4th quarter worth about $5,593,000. Finally, Lighthouse Investment Partners LLC purchased a new stake in Bruker during the fourth quarter worth approximately $3,366,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

Shares of BRKR traded down $0.56 during trading hours on Friday, reaching $64.53. 771,893 shares of the company traded hands, compared to its average volume of 1,003,506. The stock has a fifty day simple moving average of $76.07 and a 200 day simple moving average of $77.45. Bruker Co. has a fifty-two week low of $53.79 and a fifty-two week high of $94.86. The stock has a market capitalization of $9.38 billion, a PE ratio of 23.47, a price-to-earnings-growth ratio of 2.49 and a beta of 1.25. The company has a quick ratio of 0.91, a current ratio of 1.81 and a debt-to-equity ratio of 0.95.

Bruker (NASDAQ:BRKRGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.07. The business had revenue of $721.70 million for the quarter, compared to the consensus estimate of $729.88 million. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.64 earnings per share. As a group, research analysts predict that Bruker Co. will post 2.66 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, June 17th. Investors of record on Monday, June 3rd will be issued a $0.05 dividend. The ex-dividend date of this dividend is Monday, June 3rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.31%. Bruker’s payout ratio is 7.27%.

Wall Street Analyst Weigh In

BRKR has been the topic of several research analyst reports. Stifel Nicolaus cut their price target on shares of Bruker from $81.00 to $77.00 and set a “hold” rating on the stock in a research note on Monday, May 20th. UBS Group raised their price target on Bruker from $94.00 to $102.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Jefferies Financial Group initiated coverage on shares of Bruker in a research report on Monday, June 3rd. They set a “buy” rating and a $85.00 target price on the stock. The Goldman Sachs Group lifted their price objective on shares of Bruker from $66.00 to $74.00 and gave the company a “sell” rating in a research note on Wednesday, April 10th. Finally, StockNews.com lowered shares of Bruker from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Bruker presently has an average rating of “Moderate Buy” and an average price target of $85.00.

Read Our Latest Analysis on BRKR

Bruker Company Profile

(Free Report)

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Featured Stories

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKRFree Report).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.